XL MLL plus consists of an orange-labeled probe hybridizing proximal to the KMT2A gene region at 11q23.3 and a green-labeled probe hybridizing distal to the KMT2A gene region at 11q23.3.

Probe maps are created in accordance with the intended purpose of the product. Solid colored bars do not necessarily indicate that the probe fully covers the indicated genomic region. Therefore, caution is advised when interpreting results generated through off-label use. Probe map details based on UCSC Genome Browser GRCh37/hg19. Map components not to scale. Further information is available on request.

A number of recurrent chromosomal abnormalities have been shown to have prognostic significance in acute lymphoblastic leukemia (ALL), especially in B-precursor ALL. Some chromosomal abnormalities, such as high hyperdiploidy and the TEL-AML1 fusion, are associated with more favorable outcomes, while others, including the t(9;22), rearrangements of the KMT2A gene (chromosome 11q23), and intrachromosomal amplification of the AML1 gene (iAMP21), are associated with a poorer prognosis.

Chromosomal rearrangements involving the human KMT2A gene are recurrently associated with the disease phenotype of acute leukemias. The identification of KMT2A gene rearrangements is necessary for rapid clinical decisions resulting in specific therapy regimens. Amplification of KMT2A in myelodysplastic syndrome and acute myeloid leukemia has also been observed, and transcriptional similarities between KMT2A amplified and KMT2A rearranged leukemias were identified.

Clinical Applications

• Acute Lymphoblastic Leukemia (ALL)
• Acute Myelogenous Leukemia (AML)

XL MLL plus hybridized to bone marrow cells. Two aberrant interphase nuclei with one fusion signal and one separate orange and green signal each are shown, representing a translocation with KTM2A involvement.

• Poppe et al (2004) Blood 103:229-235
• Meyer et al (2006) Leukemia 20:777-784
• Cavazzini et al (2006) Haematologica 91:381-385